A systemic inflammation score derived from routine blood cell counts accurately predicts clinical outcomes and survival rates in patients with metastatic pancreatic ductal adenocarcinoma, according to a study published in Pancreatology by researchers from the Spanish Society of Medical Oncology (SEOM). Patients with lower scores on the systemic inflammation response index (SIRI) showed a significantly longer median overall survival of 14.0 months, compared to 9.2 months for those with elevated scores.
Validation of the Systemic Inflammation Response Index in Real-World Cohorts
Systemic inflammation is a core biological feature of pancreatic ductal adenocarcinoma, impacting both the tumor microenvironment and overall systemic health while intertwining with cancer-associated cachexia. Because profiling cytokines routinely remains difficult in clinical practice, blood-count-derived formulas serve as accessible alternatives to gauge inflammatory status. The SIRI metric integrates innate immune activation and adaptive immune suppression by calculating counts from neutrophils, monocytes, and lymphocytes. To validate its prognostic value in routine clinical settings, the PANTHEIA research group evaluated 672 patients with metastatic disease who started first-line chemotherapy across 30 Spanish hospitals between 2015 and 2025, according to the study data.
Beyond survival metrics, the study tracked objective response rates and disease control. Patients exhibiting lower baseline SIRI values achieved a 37 percent objective response rate and a 64 percent disease control rate. In contrast, patients with elevated index values recorded a 25 percent objective response rate and a 44 percent disease control rate.
Continuous Risk Gradation Beyond Binary Thresholds
Rather than relying strictly on a single cutoff point, researchers modeled the inflammation index as a continuous variable using flexible statistical techniques. After adjusting for functional status, tumor burden, chemotherapy regimens, and cachexia, investigators found the index remained independently associated with both overall survival and progression-free survival. Furthermore, higher continuous scores correlated directly with a lower probability of achieving an objective response.
The statistical modeling revealed a non-linear relationship where patient risk increased more sharply past specific thresholds rather than following a uniform gradient. This dynamic indicates that exceedingly high scores point to substantially greater biological risk than moderately elevated values, a nuanced distinction that a rigid single cutoff would miss. While the index also associated with higher hepatic tumor burden and cachexia, adjusting for cachexia minimally altered its relationship with survival, suggesting the SIRI metric supplies largely independent prognostic information.
Clinical Applicability and Comparative Performance
When evaluated against other blood-count formulas measuring inflammatory burden—such as the neutrophil-to-lymphocyte ratio—the SIRI score demonstrated superior statistical adjustment for predicting overall survival. Both formulas performed comparably when predicting progression-free survival and therapeutic response rates. Despite these robust statistical correlations, study authors emphasize that observational design and treatment heterogeneity in real-world practice limit definitive causal conclusions, leaving some degree of residual confounding possible.
Investigators advise against using the score to alter or withdraw standard chemotherapy regimens. Instead, they position the index as an additional prognostic layer designed to flag biologically fragile patient profiles, prioritize nutritional and supportive care, and serve as an effective stratification variable for clinical trials focused on modulating host inflammation. As a low-cost, accessible tool, the metric enriches individualized patient discussions without replacing established clinical risk factors.